Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial

Authors

• Youyi Fong, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
• Lauren Dang, Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
• Bo Zhang, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
• Jonathan Fintzi, Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
• Shiyu Chen, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
• Jing Wang, Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
• Nadine G. Rouphael, Hope Clinic, Emory University, Decatur, Georgia, USA.
• Angela R. Branche, Vaccine and Treatment Evaluation Unit, University of Rochester, Rochester, New York, USA.
• David J. Diemert, George Washington Vaccine Research Unit, George Washington University, Washington, District of Columbia, USA.
• Ann R. Falsey, Vaccine and Treatment Evaluation Unit, University of Rochester, Rochester, New York, USA.
• Cecilia Losada, Hope Clinic, Emory University, Decatur, Georgia, USA.
• Lindsey R. Baden, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
• Sharon E. Frey, Center for Vaccine Development, Saint Louis University, Missouri, USA.
• Jennifer A. Whitaker, Department of Molecular Virology and Microbiology and Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
• Susan J. Little, Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla, California, USA.
• Satoshi Kamidani, Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Georgia, USA.
• Emmanuel B. Walter, Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
• Richard M. Novak, Project WISH, University of Illinois at Chicago, Chicago, Illinois, USA.
• Richard Rupp, Department of Pediatrics, University of Texas Medical Branch, Galveston, Texas, USA.
• Lisa A. Jackson, Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.
• Chenchen Yu, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
• Craig A. Magaret, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
• Cindy Molitor, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
• Bhavesh Borate, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
• Tara M. Babu, Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.
• Angelica C. Kottkamp, Vaccine and Treatment Evaluation Unit, Manhattan Research Clinic, New York University Grossman School of Medicine, New York, New York, USA.
• Anne F. Luetkemeyer, Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, California, USA.
• Lilly C. Immergluck, Clinical Research Center, Department of Microbiology, Biochemistry, and Immunology, Morehouse School of Medicine, Atlanta, Georgia, USA.
• Rachel M. Presti, Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA.
• Martín Bäcker, Vaccine and Treatment Evaluation Unit, Long Island Research Clinic, New York University, Long Island School of Medicine, Mineola, New York, USA.
• Patricia L. Winokur, Department of Medicine, University of Iowa College of Medicine, Iowa City, Iowa, USA.
• Siham M. Mahgoub, Howard University College of Medicine, Howard University Hospital, Washington, District of Columbia, USA.

Document Type

Journal Article

Publication Date

9-26-2024

Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

DOI

10.1093/cid/ciae465

Keywords

COVID-19 booster; Omicron; correlate of risk; exposure-proximal titer; variant vaccine booster

Abstract

For COVAIL recipients of a COVID-19 Sanofi booster vaccine, neutralizing antibody titers were assessed as a correlate of risk (CoR) of COVID-19. Peak and exposure-proximal titers were inverse CoRs with covariate-adjusted hazard ratios (95% confidence intervals) 0.30 (0.11, 0.78) and 0.25 (0.07, 0.85) per 10-fold increase in weighted average titer.

APA Citation

Fong, Youyi; Dang, Lauren; Zhang, Bo; Fintzi, Jonathan; Chen, Shiyu; Wang, Jing; Rouphael, Nadine G.; Branche, Angela R.; Diemert, David J.; Falsey, Ann R.; Losada, Cecilia; Baden, Lindsey R.; Frey, Sharon E.; Whitaker, Jennifer A.; Little, Susan J.; Kamidani, Satoshi; Walter, Emmanuel B.; Novak, Richard M.; Rupp, Richard; Jackson, Lisa A.; Yu, Chenchen; Magaret, Craig A.; Molitor, Cindy; Borate, Bhavesh; Babu, Tara M.; Kottkamp, Angelica C.; Luetkemeyer, Anne F.; Immergluck, Lilly C.; Presti, Rachel M.; Bäcker, Martín; Winokur, Patricia L.; and Mahgoub, Siham M., "Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial" (2024). GW Authored Works. Paper 5588.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/5588

Department

Medicine